Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bank of Montreal — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.51 (market cap $39.89B), while Bank of Montreal trades at $179.87 (market cap $125.01B). The key difference: Bank of Montreal is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Bank of Montreal pays a 2.77% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BMO | |
|---|---|---|
Market Cap | $39.89B | $125.01B |
Sector | Health | Financials |
52-Week High | $491.22 | $178.96 |
52-Week Low | $278.09 | $110.44 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BMO trades at $178.96, up 1.3% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 34% YoY net income growth in Q2 2026 and a 25.92% net margin. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings. The company maintains robust cash flow and a solid balance sheet with $84.25B in equity.
Outlook remains positive driven by earnings beats and expansion in metals & mining. Risks include valuation concerns at a P/E of 19.51 and interest rate sensitivity. The stock offers a steady dividend yield, but investors should monitor integration of recent acquisitions and macroeconomic pressures on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
